Jazz Pharmaceuticals, Inc.
United States
510 articles about Jazz Pharmaceuticals, Inc.
-
Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.
-
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
11/8/2023
Jazz Pharmaceuticals plc announced financial results for the third quarter of 2023 and provided business updates.
-
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers
11/7/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.
-
Jazz Pharmaceuticals to Participate in Upcoming November 2023 Investor Conferences
11/1/2023
Jazz Pharmaceuticals plc announced that Company management will participate in the following upcoming investor conferences.
-
Jazz Pharmaceuticals to Report 2023 Third Quarter Financial Results on November 8, 2023
10/25/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 third quarter financial results on Wednesday, November 8, 2023, after the close of the U.S. financial markets.
-
Jazz Pharmaceuticals Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xywav®
10/23/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced new data that examine the comorbid risk of cardiovascular disease in patients with narcolepsy and idiopathic hypersomnia as well as the effect of sodium intake on cardiovascular health.
-
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
10/18/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present 14 abstracts from across its sleep medicine portfolio, including two oral presentations, at the 17th annual World Sleep 2023 Congress, held October 20-25 in Rio de Janeiro, Brazil.
-
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
9/22/2023
Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze ® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
-
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
9/21/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Commission (EC) has granted marketing authorization for Enrylaze® (JZP458; a recombinant Erwinia asparaginase or crisantaspase) for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase.
-
Jazz Pharmaceuticals to Participate in Three Upcoming Investor Conferences - September 13, 2023
9/13/2023
Jazz Pharmaceuticals plc announced that Company management will participate in three upcoming investor conferences.
-
Jazz Pharmaceuticals Announces Key Update to Leadership Team
9/12/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Renée Galá, Chief Financial Officer, has been promoted to President and Chief Operating Officer effective October 1, 2023.
-
Jazz Pharmaceuticals Showcases Impact of Sleep Medicine Portfolio at Psych Congress 2023
9/11/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six abstracts presenting data from across its sleep medicine portfolio were featured at the 36th annual Psych Congress, held September 6-10, 2023.
-
Jazz Pharmaceuticals to Participate in Citi's 18th Annual BioPharma Conference
8/24/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the Citi Annual BioPharma Conference in Boston. Company management will participate in a fireside chat on Thursday, September 7, 2023, at 8:20 a.m. PT / 11:20 a.m. ET / 4:20 p.m. IST.
-
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
8/9/2023
Jazz Pharmaceuticals plc announced financial results for the second quarter of 2023, raised 2023 full year financial guidance and provided business updates.
-
Jazz Pharmaceuticals to Report 2023 Second Quarter Financial Results on August 9, 2023
7/26/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 second quarter financial results on Wednesday, August 9, 2023, after the close of the U.S. financial markets.
-
Jazz Pharmaceuticals Receives CHMP Positive Opinion for JZP458 (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
7/21/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the marketing authorization of JZP458.
-
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
6/2/2023
Jazz Pharmaceuticals plc and Zymeworks Inc. presented positive pivotal trial data, including new data on progression-free survival, from the Phase 2b HERIZON-BTC-01 trial of the bispecific antibody zanidatamab in previously treated HER2-amplified biliary tract cancers.
-
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
5/31/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 3-7, 2023.
-
Jazz Pharmaceuticals to Participate in the 2023 Goldman Sachs Global Healthcare Conference
5/30/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 Goldman Sachs Global Healthcare Conference.
-
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
5/25/2023
Jazz Pharmaceuticals plc will host a webcast to review the zanidatamab biliary tract cancers data being featured in an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting on June 2, 2023.